EA201890979A1 - Стабильные белковые композиции - Google Patents

Стабильные белковые композиции

Info

Publication number
EA201890979A1
EA201890979A1 EA201890979A EA201890979A EA201890979A1 EA 201890979 A1 EA201890979 A1 EA 201890979A1 EA 201890979 A EA201890979 A EA 201890979A EA 201890979 A EA201890979 A EA 201890979A EA 201890979 A1 EA201890979 A1 EA 201890979A1
Authority
EA
Eurasian Patent Office
Prior art keywords
therapeutic biomolecule
biomolecule
therapeutic
porous structure
environment
Prior art date
Application number
EA201890979A
Other languages
English (en)
Other versions
EA036623B1 (ru
Inventor
Хантер Чен
Эрика Шлезингер
Original Assignee
Ридженерон Фармасьютикалз, Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ридженерон Фармасьютикалз, Инк. filed Critical Ридженерон Фармасьютикалз, Инк.
Publication of EA201890979A1 publication Critical patent/EA201890979A1/ru
Publication of EA036623B1 publication Critical patent/EA036623B1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/179—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A61K9/0051—Ocular inserts, ocular implants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08L—COMPOSITIONS OF MACROMOLECULAR COMPOUNDS
    • C08L71/00—Compositions of polyethers obtained by reactions forming an ether link in the main chain; Compositions of derivatives of such polymers
    • C08L71/08—Polyethers derived from hydroxy compounds or from their metallic derivatives
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08L—COMPOSITIONS OF MACROMOLECULAR COMPOUNDS
    • C08L2203/00—Applications
    • C08L2203/02—Applications for biomedical use

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Ophthalmology & Optometry (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Polymers & Plastics (AREA)
  • Zoology (AREA)
  • Cell Biology (AREA)
  • Inorganic Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Media Introduction/Drainage Providing Device (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Описаны стабильные фармацевтические лекарственные формы и устройства доставки лекарственных средств. В некоторых вариантах реализации изобретения устройство доставки лекарственного средства содержит резервуар, который после имплантации в организм пациента находится в частичном контакте с тканевой окружающей средой. Резервуар остается в контакте с окружающей средой с помощью пористой структуры в корпусе устройства доставки. Резервуар содержит комбинацию терапевтической биомолекулы и второй молекулы, которая служит для стабилизации и ограничения растворимости терапевтической биомолекулы, тем самым контролируя количество терапевтической биомолекулы, которое находится в растворе. Концентрация растворимой терапевтической биомолекулы или размер площади поверхности пористой структуры контролируют скорость доставки терапевтической биомолекулы к целевой ткани.
EA201890979A 2015-10-16 2016-10-14 Стабильные белковые композиции EA036623B1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562242412P 2015-10-16 2015-10-16
PCT/US2016/057019 WO2017066554A1 (en) 2015-10-16 2016-10-14 Stable protein compositions

Publications (2)

Publication Number Publication Date
EA201890979A1 true EA201890979A1 (ru) 2018-10-31
EA036623B1 EA036623B1 (ru) 2020-12-01

Family

ID=57209897

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201890979A EA036623B1 (ru) 2015-10-16 2016-10-14 Стабильные белковые композиции

Country Status (12)

Country Link
US (1) US20180289623A1 (ru)
EP (1) EP3362041A1 (ru)
JP (3) JP6853245B2 (ru)
KR (1) KR20180063311A (ru)
CN (2) CN108348462B (ru)
AU (2) AU2016340072B2 (ru)
CA (1) CA3001346A1 (ru)
EA (1) EA036623B1 (ru)
IL (2) IL310557A (ru)
MX (2) MX2018004695A (ru)
MY (1) MY193964A (ru)
WO (1) WO2017066554A1 (ru)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11291636B2 (en) 2011-11-18 2022-04-05 Regeneron Pharmaceuticals, Inc. Polymer protein microparticles

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA036623B1 (ru) * 2015-10-16 2020-12-01 Ридженерон Фармасьютикалз, Инк. Стабильные белковые композиции
US20200338164A1 (en) * 2017-11-17 2020-10-29 Amgen Inc. Vegfr-fc fusion protein formulations
JOP20200275A1 (ar) 2018-05-10 2020-11-02 Regeneron Pharma صيغ تحتوي على بروتين اندماج لمستقبلvegf مرتفعة التركيز
KR20200029374A (ko) * 2018-09-10 2020-03-18 삼성바이오에피스 주식회사 단백질을 포함하는 액상 조성물
CN112294760A (zh) * 2019-07-26 2021-02-02 张晋宇 一种液体制剂及其应用

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK0661989T3 (da) * 1992-09-21 1998-03-02 Upjohn Co Proteinsammensætninger med vedvarende frigivelse
US6004549A (en) * 1994-12-14 1999-12-21 Schering Corporation Crystalline protein controlled release compositions
BR0317888A (pt) * 2002-12-31 2005-12-06 Altus Pharmaceuticals Inc Cristais do hormÈnio do crescimento humano e processos para preparação dos mesmos
US8815284B2 (en) * 2003-06-26 2014-08-26 Psivida Us, Inc. Bioerodible sustained release drug delivery systems
MX2007006214A (es) * 2004-11-24 2008-04-16 Therakine Ltd Un implante para suministro de farmaco intraocular.
CA2654510C (en) 2006-06-16 2015-03-17 Regeneron Pharmaceuticals, Inc. Vegf antagonist formulations suitable for intravitreal administration
US20100318193A1 (en) 2007-03-08 2010-12-16 Desai Tejal A Topographically engineered structures and methods for using the same in regenerative medicine applications
EP3000434A1 (en) 2007-03-16 2016-03-30 The Regents Of The University Of California Nanostructure surface coated medical implants and methods of using the same
US8623395B2 (en) * 2010-01-29 2014-01-07 Forsight Vision4, Inc. Implantable therapeutic device
SG173167A1 (en) * 2009-01-29 2011-08-29 Forsight Labs Llc Posterior segment drug delivery
CN101559041B (zh) * 2009-05-19 2014-01-15 中国科学院过程工程研究所 粒径均一的多肽药物缓释微球或微囊制剂及制备方法
US8417452B2 (en) 2009-08-19 2013-04-09 General Motors Llc System for providing information to an operator of a vehicle
EP2600930B1 (en) 2010-08-05 2021-02-17 ForSight Vision4, Inc. Injector apparatus for drug delivery
JP5907966B2 (ja) * 2010-08-05 2016-04-26 フォーサイト・ビジョン フォー・インコーポレーテッド 埋め込み型治療デバイス
US10864158B2 (en) 2011-04-14 2020-12-15 The Regents Of The University Of California Multilayer thin film drug delivery device and methods of making and using the same
IN2014DN10765A (ru) 2012-05-30 2015-09-04 Univ California
WO2014039964A2 (en) 2012-09-10 2014-03-13 The Regents Of The University Of California Compounds and methods for modulating vascular injury
WO2016010924A1 (en) * 2014-07-14 2016-01-21 Amgen Inc. Crystalline antibody formulations
KR101808234B1 (ko) 2015-06-23 2017-12-12 (주)알테오젠 IgG Fc 도메인을 가지는 융합 단백질의 안정한 액상 제제
EA036623B1 (ru) 2015-10-16 2020-12-01 Ридженерон Фармасьютикалз, Инк. Стабильные белковые композиции

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11291636B2 (en) 2011-11-18 2022-04-05 Regeneron Pharmaceuticals, Inc. Polymer protein microparticles
US11951216B2 (en) 2011-11-18 2024-04-09 Regeneron Pharmaceuticals, Inc. Polymer protein microparticles

Also Published As

Publication number Publication date
IL258570B2 (en) 2024-07-01
JP2023025046A (ja) 2023-02-21
WO2017066554A1 (en) 2017-04-20
CN113827704B (zh) 2024-07-12
EP3362041A1 (en) 2018-08-22
AU2016340072B2 (en) 2021-10-28
KR20180063311A (ko) 2018-06-11
IL258570A (en) 2018-05-31
JP7179112B2 (ja) 2022-11-28
JP6853245B2 (ja) 2021-03-31
EA036623B1 (ru) 2020-12-01
AU2022200475A1 (en) 2022-02-17
AU2022200475B2 (en) 2023-09-14
MY193964A (en) 2022-11-03
CN108348462B (zh) 2021-10-15
BR112018007507A2 (pt) 2018-10-23
JP2018538243A (ja) 2018-12-27
CA3001346A1 (en) 2017-04-20
MX2018004695A (es) 2019-03-14
JP2021098742A (ja) 2021-07-01
MX2022003376A (es) 2022-04-12
AU2016340072A1 (en) 2018-05-10
CN113827704A (zh) 2021-12-24
IL310557A (en) 2024-03-01
IL258570B1 (en) 2024-03-01
US20180289623A1 (en) 2018-10-11
CN108348462A (zh) 2018-07-31

Similar Documents

Publication Publication Date Title
EA201890979A1 (ru) Стабильные белковые композиции
CY1124675T1 (el) Σταθερη καθορισμενης δοσης φαρμακευτικη συνθεση που περιλαμβανει μομεταζονη και ολοπαταδινη για ρινικη χορηγηση
CO2017004596A2 (es) Formulación estable de proteina en solucion que contiene una alta concentracion de un anticuerpo anti-vegf
BR112015022433A2 (pt) dispositivos de liberação de droga com componente permeável à droga e métodos
EA201892595A1 (ru) Назальные фармацевтические композиции с пористым наполнителем
EA201590058A1 (ru) Аналоги глюкагона
AR107014A1 (es) Formulación farmacéutica acuosa
TW200637615A (en) Therapeutic peptide formulations with improved stability
CL2012002326A1 (es) Uso de una combinación de por lo menos un agente quimioterapéutico y una cantidad efectiva de un anticuerpo anti-vegf (factor de crecimiento endotelial vascular), porque sirve para preparar un medicamento útil en el tratamiento de cáncer ovárico; y su kit para tratar el cáncer ovárico sin tratamiento anterior en una paciente humana.
AR100353A1 (es) Droga de direccionamiento a glipicano 3 (gpc3) que se administra a un paciente que responde a la terapia con drogas de direccionamiento a gpc3
BR112017025108A2 (pt) compostos seletivos de pyy e usos dos mesmos
EA201492292A1 (ru) Препарат антител
WO2013078257A3 (en) Implantable solid-liquig drug delivery apparatus, formulations, and methods of use
AR105712A1 (es) Composiciones de insulina de rápida acción
UY36542A (es) Formulaciones farmacéuticas para anticuerpos anti-tnf-alfa
MX2019014942A (es) Dispositivos de administracion de farmacos bioerosionables.
EA201692392A1 (ru) Новая лекарственная форма мелоксикама
EA201992272A1 (ru) Ацилированное инсулиновое соединение
CY1113575T1 (el) Χρηση συνθεσεων οπιοειδων σε συσκευες χορηγησης δραστικης ουσιας χωρις βελονα
PE20211492A1 (es) Composiciones estables de semaglutida y usos de las mismas
EA202090508A1 (ru) Изготовление фармацевтических составов
JP2016518932A5 (ru)
AU2015242791A1 (en) Drug Delivery Enhancer Comprising Substance For Activating Lysophospholipid Receptors
EA202090242A1 (ru) Лечение болезни фабри у фзт-наивных и фзт-леченных пациентов
MX2012012976A (es) Cateter que permite dosificacion variable de un agente activo.